#United States #New York #Rosen Law Firm #Tandem Diabetes Care #TNDM

Overview of the Situation

Rosen Law Firm, a prominent global law firm specializing in investor rights, has initiated an investigation regarding potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). This investigation arises from allegations indicating that the company may have disseminated materially misleading information concerning its business operations to investors. Significant events, particularly the company’s press release on August 7, 2025, prompted a drastic reaction in the stock market.

Key Incident

On the morning of August 7, Tandem Diabetes Care announced a voluntary medical device correction concerning select tslim X2 insulin pumps. The company's release disclosed the identification of a potential issue with the device that could lead to an error, thus possibly interrupting insulin delivery. This information resulted in a sharp 19.9% decline in the company's stock on the same day, signaling investor concern and dissatisfaction. Thereafter, the Rosen Law Firm stepped forward to investigate the circumstances surrounding this incident and the overall context regarding the company’s communication to investors.

Legal Recourse and Investor Actions

The Rosen Law Firm is preparing a class action lawsuit seeking recovery of the losses experienced by investors. Those who purchased Tandem Diabetes Care securities may have the opportunity to seek compensation without incurring any out-of-pocket costs, as the law firm operates under a contingency fee arrangement. Investors impacted are encouraged to join the prospective class action by either filling out a form on the firm’s dedicated website or contacting Phillip Kim, Esq. directly for further information.

Why Choose Rosen Law Firm?

Selecting qualified legal representation is imperative in cases such as these. Rosen Law Firm advocates for investors around the globe, focusing on securities class actions and shareholder derivative litigation. The firm has an impressive track record, recognized by various legal accolades and achievements. In 2019, they secured over $438 million for their clients and have consistently ranked highly by ISS Securities Class Action Services, showcasing their commitment to representing investor interests effectively. Rosen and his team have garnered accolades, with many attorneys featured in prestigious listings such as Lawdragon and Super Lawyers.

Conclusion

Investors holding Tandem Diabetes Care securities during the mentioned timeframe should consider their legal options, particularly in light of the recent market response to the company’s disclosures. The Rosen Law Firm emphasizes the importance of qualified legal counsel, encouraging investors to remain informed on the progress of this investigation and potential class action suit. Keeping updated through professional channels such as LinkedIn, Twitter, or Facebook may be beneficial for those seeking more information on this matter.

For those interested in the legal implications and opportunities arising from this situation, reaching out to Rosen Law Firm could be a prudent step toward understanding one’s rights as an investor.

Contact Information

Investment consultations can be arranged with the Rosen Law Firm, through phone or by visiting their online platforms. The firm welcomes inquiries and is dedicated to assisting shareholders in navigating the complexities of investor claims.

• - Laurence Rosen, Esq.
• - Phillip Kim, Esq.
• - The Rosen Law Firm, P.A.
• - 275 Madison Avenue, 40th Floor, New York, NY 10016
• - Phone: (212) 686-1060
• - Toll-Free: (866) 767-3653
• - Facebook: Rosen Law Firm
• - Twitter: @rosen_firm
• - LinkedIn: Rosen Law Firm